Unlock instant, AI-driven research and patent intelligence for your innovation.

Modafinil compositions

A technology of a composition and a drug, applied in the field of compositions containing modafinil, can solve problems such as poor solubility

Inactive Publication Date: 2011-04-13
CEPHALON INC
View PDF24 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, crystalline polymorphs typically have different solubilities from each other such that thermodynamically more stable polymorphs are less soluble than thermodynamically less stable polymorphs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modafinil compositions
  • Modafinil compositions
  • Modafinil compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0155] 2:1 R-(-)-modafinil:S-(+)-modafinil

[0156] Bubble anhydrous ammonia through methanol containing R-benzhydrylsulfinylmethyl ester (8.62 g, 0.0299 mol, about 80:20 R-isomer:S-isomer by weight) (125 mL) solution for 10 minutes. Pressure build-up from the reaction caused sodium bicarbonate to flow back from the retort into the reaction mixture. The reaction was stopped and the precipitate was collected. The filtrate was concentrated under reduced pressure to obtain a yellow solid residue (2.8 g). The yellow solid was columned (silica gel, grade 9385, 230-400 mesh, 60 Angstroms) with 3:1 v / v ethyl acetate:hexane as eluent. The filtrates were then combined and concentrated under reduced pressure to give a slightly yellowish solid (most of the yellow color remained on the column). The solid was then recrystallized from ethanol by heating the mixture until it boiled and then cooled to room temperature to give 2:1 R-(-)-modafinil:S-(+)-modafinil as a colorless solid (580m...

Embodiment 2

[0160] Polymorphs of R-(-)-modafinil

[0161] Several polymorphs of R-(-)-modafinil were observed, each characterized by PXRD. image 3 , 6 , and 9 represent these PXRD diffractograms (data obtained for direct collection) of the Form III, Form IV, and Form V polymorphs.

[0162] Recrystallization has proven to be an efficient technique for forming and obtaining polymorphs of R-(-)-modafinil. Suitable solvents for crystallization of one or more polymorphs of R-(-)-modafinil include, but are not limited to, acetonitrile, dimethylformamide (DMF), methanol, methyl ethyl ketone , N-methylpyrrolidone, ethanol, isopropanol, isobutanol, formamide, isobutyl acetate, 1,4-dioxane, tetrahydrofuran (THF), ethyl acetate, o-xylene, acetic acid Isopropyl ester, methylene chloride, propylene glycol, acetic acid, water, acetone, nitromethane, toluene, and benzyl alcohol. Pure solvents and mixtures of solvents can be used for the crystallization of one or more polymorphs of R-(-)-modafinil. ...

Embodiment 3

[0188] 2:1 R-(-)-modafinil:S-(+)-modafinil

[0189] A solution containing R-(-)-modafinil (80.16 mg, 0.293 mmol) and racemic modafinil (20.04 mg, 0.0366 mmol) in ethanol (2 mL) was prepared. The mixture was heated to boiling to dissolve all solids, then cooled to room temperature (25°C). After 15 minutes at room temperature, the solution was allowed to stand overnight at 5°C. The solution was then decanted off and the remaining crystals were dried under nitrogen flow and characterized using HPLC, PXRD, DSC, and thermal microscopy.

[0190] The resulting crystals contained about 63 to about 67% R-(-)-modafinil, with the remainder of the crystals being S-(+)-modafinil. HPLC analysis showed that the crystals were a 2:1 phase containing two R-(-)-modafinil molecules per S-(+)-modafinil molecule.

[0191] PXRD was performed on single crystal samples of 2:1 R-(-)-modafinil:S-(+)-modafinil. 2:1 R-(-)-modafinil:S-(+)-modafinil can pass Figure 11 Any one, any two, any three, any ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.

Description

technical field [0001] The present invention relates to a composition comprising modafinil, a pharmaceutical composition comprising modafinil, and a preparation method thereof. Background technique [0002] The active pharmaceutical ingredient (API) in the pharmaceutical composition can be prepared in a variety of different forms. Such APIs can be prepared in a variety of different chemical forms including chemical derivatives, solvates, hydrates, co-crystals or salts. Such APIs can also be prepared to have different physical forms. For example, an API may be amorphous, may have different crystalline polymorphs, or may exist in different solvated or hydrated states. By changing the form of the API, it is possible to change its physical properties. For example, crystalline polymorphs typically have different solubilities from each other such that thermodynamically more stable polymorphs are less soluble than thermodynamically less stable polymorphs. Pharmaceutical polymor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07C317/10A61K31/165
Inventor 马加利·布戈尔·希基马修·彼得松厄恩·奥尔马松马克·奥利韦拉
Owner CEPHALON INC